BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28182747)

  • 1. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.
    Kenmogne LC; Roy J; Maltais R; Rouleau M; Neveu B; Pouliot F; Poirier D
    PLoS One; 2017; 12(2):e0171871. PubMed ID: 28182747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
    Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
    Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.
    Cortés-Benítez F; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2017 Apr; 25(7):2065-2073. PubMed ID: 28254377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of a dansyl-labeled inhibitor of 17β-hydroxysteroid dehydrogenase type 3 for optical imaging.
    Kenmogne LC; Maltais R; Poirier D
    Bioorg Med Chem Lett; 2016 May; 26(9):2179-83. PubMed ID: 27025340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Med Chem; 2019 Aug; 62(15):7070-7088. PubMed ID: 31268309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprint of "In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3".
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2015 Sep; 153():170-8. PubMed ID: 26291835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
    Ning X; Yang Y; Deng H; Zhang Q; Huang Y; Su Z; Fu Y; Xiang Q; Zhang S
    Steroids; 2017 May; 121():10-16. PubMed ID: 28267564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Maltais R; Fournier MA; Poirier D
    Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
    Bellavance E; Luu-The V; Poirier D
    J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
    Laplante Y; Poirier D
    Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
    Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
    Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
    Bydal P; Luu-The V; Labrie F; Poirier D
    Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3.
    Provost PR; Blomquist CH; Godin C; Huang XF; Flamand N; Luu-The V; Nadeau D; Tremblay Y
    Endocrinology; 2000 Aug; 141(8):2786-94. PubMed ID: 10919264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
    Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
    Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.